Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

  title={Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis},
  author={Stefan Leucht and Caroline Corves and D Arbter and Rolf R. Engel and Chunbo Li and John M. Davis},
  journal={The Lancet},

Figures and Tables from this paper

Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia.
Perphenazine and low-potency antipsychotic drugs seemed to be similar in terms of the primary outcome - response to treatment, however results were imprecise and there was no clear evidence of a difference in acceptability of treatment.
A Meta-Analysis of Randomized Control Trial on the Efficacy of Second Generation Antipsychotics
Second generation antipsychotic is superior in reducing total PANSS score than first generation antippsychotic, and resperidone and olanzapine, they are homogenous in reduced total PAN SS score.
Antipsychotics in Adults With Schizophrenia: Comparative Effectiveness of First-Generation Versus Second-Generation Medications
Clear benefits of FGAs versus SGAs for treating schizophrenia remain inconclusive because of variation in assessing outcomes and lack of clinically important differences for most comparisons.
Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia.
No clear evidence that haloperidol was superior to low-potency antipsychotic drugs in terms of clinical response was found and there was also no clear evidence of benefit for either group in acceptability of treatment with equivocal results.
Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia.
There was no significant difference between fluphenazine and low-potency antipsychotics for numbers experiencing at least one adverse effect, and the results of the primary outcome were robust in a number of subgroup and sensitivity analyses.
Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders.
A high-quality systematic review of the efficacy, acceptability, and tolerability of haloperidol with other first-generation antipsychotic drugs in schizophrenia and schizophrenia-like psychosis found that haloperIDol alleviated more positive symptoms of schizophrenia than the other antipsychotics.
Comparing effectiveness of risperidone with first-generation antipsychotic medications in patients with schizophrenia-spectrum disorders
It is concluded that there is a very high rate of discontinuation of the initial antipsychotic medications for various reasons, with risperidone having an overall longer time to discontinuation compared with first-generation antipsychotics medications.
Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis.
In FES, olanzapine, amisulpride and, less so, risperidone and quetiapine showed superior efficacy, greater treatment persistence and less EPS than FGAs.


Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.
Treatment with perphenazine was less costly than treatment with second-generation antipsychotics with no significant differences in measures of effectiveness, but the trial was limited by a high dropout rate, and longer-term neurological and metabolic side effects require further study.
How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials
It is concluded that the drug versus placebo difference of SGA drugs and haloperidol in recent trials was moderate, and that there is much room for more efficacious compounds.
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Olanzapine was the most effective in terms of the rates of discontinuation, and the efficacy of the conventional antipsychotic agent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone.
Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy.
  • L. Davies, S. Lewis, H. Lloyd
  • Medicine, Psychology
    The British journal of psychiatry : the journal of mental science
  • 2007
Conventional antipsychotics may be cost-saving and associated with a gain in QALYs compared with atypical antipsychotic drugs, according to the primary and sensitivity analyses.
Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
In people with schizophrenia whose medication is changed for clinical reasons, there is no disadvantage across 1 year in terms of quality of life, symptoms, or associated costs of care in using FGAs rather than nonclozapine SGAs.
Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis
There is no clear evidence that atypical antipsychotics are more effective or are better tolerated than conventional antipsychotic drugs.
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
After 2 months of antipsychotic treatment, all groups had a small but significant improvement in neurocognition, and after 18 months of treatment, neurocognitive improvement was greater in the perphenazine group than in the olanzapine and risperidone groups.
Clinical trial-based cost-effectiveness analyses of antipsychotic use.
There is no clear evidence that atypical antipsychotics generate cost savings or are cost-effective in general use among all schizophrenia patients, and Psychiatrists, researchers, and administrators should consider the methodological issues highlighted in interpreting study results.
Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine.
Aripiprazole and perphenazine, at the doses used here, can improve the symptoms of schizophrenia in treatment-resistant patients who have failed to respond to olanzapine or risperidone.